PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Endocrinology and Metabolism10.3803/enm.2021.13532022372233-242Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular DiseaseSangmo Hong, Woo Je Lee, Cheol-Young Parkhttp://e-enm.org/upload/pdf/enm-2021-1353.pdf, http://e-enm.org/journal/view.php?doi=10.3803/EnM.2021.1353, http://e-enm.org/upload/pdf/enm-2021-1353.pdf
10.21203/rs.3.rs-38818/v12020Effect of aspirin versus cilostazol for inhibition of antiplatelet aggregation in type 2 diabetes mellitus patients (ESCORT-DM Study)Sangmo Hong, Woo Je Lee, Cheol-Young Parkhttps://www.researchsquare.com/article/rs-38818/v1, https://www.researchsquare.com/article/rs-38818/v1.html
Current Cardiovascular Risk Reports10.1007/s12170-011-0207-z20116162-70Aspirin and Other Antiplatelet Agents and Their Effects on Cardiovascular Disease in Type 2 DiabetesC. D. Williams, M. S. Kirkmanhttp://link.springer.com/content/pdf/10.1007/s12170-011-0207-z.pdf, http://link.springer.com/article/10.1007/s12170-011-0207-z/fulltext.html, http://link.springer.com/content/pdf/10.1007/s12170-011-0207-z
The Journal of Clinical Pharmacology10.1177/0091270005280377200545101172-1178Lumiracoxib Does Not Affect the Ex Vivo Antiplatelet Aggregation Activity of Low-Dose Aspirin in Healthy SubjectsJ. Jermany, J. Branson, R. Schmouder, M. Guillaume, C. Rordorfhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1177%2F0091270005280377, https://onlinelibrary.wiley.com/doi/full/10.1177/0091270005280377
Pharmacoepidemiology and Drug Safety10.1002/pds.1828200918121143-1149Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage studyLennart Welin, Lars Wilhelmsen, Arne Björnberg, Anders Odénhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpds.1828, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpds.1828, http://onlinelibrary.wiley.com/wol1/doi/10.1002/pds.1828/fullpdf
JACC: Cardiovascular Interventions10.1016/j.jcin.2014.12.011201582S2CRT-225 Outside Start Cilostazol Bridge Study (Outpatient peri-Surgical Interruption of Drug Eluting Stent Antiplatelet Regimen Testing A Cilostazol Bridge Study): A 6 year experienceCharles L. Laham, Michael S. Chandra, Nicolas W. Shammashttps://api.elsevier.com/content/article/PII:S1936879814017968?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1936879814017968?httpAccept=text/plain
Catheterization and Cardiovascular Interventions10.1002/ccd.24416201281142-49Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: Impact of high on-treatment platelet reactivity and diabetes mellitus statusPiera Capranzano, Jose Luis Ferreiro, Masafumi Ueno, Davide Capodanno, Kodlipet Dharmashankar, Andrew Darlington, Bhaloo Desai, Antonio Tello-Montoliu, Fabiana Rollini, Dominick J. Angiolillohttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fccd.24416, http://onlinelibrary.wiley.com/wol1/doi/10.1002/ccd.24416/fullpdf
Catheterization and Cardiovascular Interventions10.1002/ccd.21995200974S1S1-S6Combination antiplatelet therapy in patients with peripheral arterial disease: Is the best therapy aspirin, clopidogrel, or both?Emile R. Mohlerhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fccd.21995, https://onlinelibrary.wiley.com/doi/full/10.1002/ccd.21995
European Heart Journal10.1093/eurheartj/ehz748.0676201940Supplement_1P1929A randomized controlled trial evaluating outcome impact of cilostazol in patients with coronary artery disease and at a high risk of cardiovascular diseaseT.-H Chao, S.-Y Tseng, P.-Y Liu, Y.-H Lihttp://academic.oup.com/eurheartj/article-pdf/40/Supplement_1/ehz748.0676/30204291/ehz748.0676.pdf, http://academic.oup.com/eurheartj/article-pdf/40/Supplement_1/ehz748.0676/30204291/ehz748.0676.pdf
Diabetes10.2337/db18-417-p201867Supplement_1The Effects of Cardiovascular Risk Factor Combined Antiplatelet Therapy and the Risk of Cerebrovascular Events in Patients with T2DM in an Urban Community over 96-Month Follow-Up—The Beijing Communities Diabetes Study 19XUE LIAN ZHANG, SHEN YUAN YUAN, BCDS GROUPhttps://diabetesjournals.org/diabetes/article/67/Supplement_1/417-P/60294/The-Effects-of-Cardiovascular-Risk-Factor-Combined, https://diabetesjournals.org/diabetes/article/67/Supplement_1/417-P/60294/The-Effects-of-Cardiovascular-Risk-Factor-Combined